{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T14:03:03Z","timestamp":1788357783517,"version":"build-2803163510"},"reference-count":95,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","mayoclinicproceedings.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.mayocp.2016.12.025","type":"journal-article","created":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T12:19:10Z","timestamp":1493641150000},"page":"826-837","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Diagnosis and Management of Immune-Mediated Myopathies"],"prefix":"10.1016","volume":"92","author":[{"given":"Margherita","family":"Milone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib1","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.nmd.2014.12.001","article-title":"205th ENMC International Workshop: pathology diagnosis of idiopathic inflammatory myopathies part II 28-30 March 2014, Naarden, The Netherlands","volume":"25","author":"De Bleecker","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"10.1016\/j.mayocp.2016.12.025_bib3","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib4","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: an overdiagnosed entity","volume":"61","author":"van der Meulen","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1212\/WNL.61.3.288","article-title":"Unicorns, dragons, polymyositis, and other mythological beasts","volume":"61","author":"Amato","year":"2003","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.nmd.2015.02.014","article-title":"Myositis with endomysial cell invasion indicates inclusion body myositis even if other criteria are not fulfilled","volume":"25","author":"van de Vlekkert","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.025_bib7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1097\/WCO.0000000000000376","article-title":"Advances in serological diagnostics of inflammatory myopathies","volume":"29","author":"Benveniste","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/BOR.0b013e32834bab42","article-title":"Acquired immune and inflammatory myopathies: pathologic classification","volume":"23","author":"Pestronk","year":"2011","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.025_bib11","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pediatrneurol.2011.04.009","article-title":"Anti-signal recognition particle myopathy in the first decade of life","volume":"45","author":"Suzuki","year":"2011","journal-title":"Pediatr Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/MD.0000000000000028","article-title":"Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin","volume":"93","author":"Allenbach","year":"2014","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/mus.24689","article-title":"Camptocormia as presenting manifestation of a spectrum of myopathic disorders","volume":"52","author":"Ghosh","year":"2015","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib15","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1002\/mus.24970","article-title":"Signal recognition particle immunoglobulin G detected incidentally associates with autoimmune myopathy","volume":"53","author":"Apiwattanakul","year":"2016","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.nmd.2015.03.012","article-title":"Respiratory failure as presenting symptom of necrotizing autoimmune myopathy with anti-melanoma differentiation-associated gene 5 antibodies","volume":"25","author":"Jaeger","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib17","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/j.ijcard.2014.03.045","article-title":"Takotsubo cardiomyopathy in the setting of necrotizing myopathy","volume":"174","author":"Bangert","year":"2014","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.025_bib18","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1212\/NXI.0000000000000124","article-title":"Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology","volume":"2","author":"Alshehri","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib19","doi-asserted-by":"publisher","first-page":"e290","DOI":"10.1212\/NXI.0000000000000290","article-title":"Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy","volume":"3","author":"Kadoya","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4 pt 2","key":"10.1016\/j.mayocp.2016.12.025_bib20","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/j.lpm.2010.11.023","article-title":"Myositis or dystrophy? traps and pitfalls","volume":"40","author":"Benveniste","year":"2011","journal-title":"Presse Med"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1097\/WCO.0b013e328364e9d9","article-title":"Acquired necrotizing myopathies","volume":"26","author":"Allenbach","year":"2013","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1046\/j.1365-2990.2002.00417.x","article-title":"Muscle pathology in dysferlin deficiency","volume":"28","author":"Fanin","year":"2002","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1-2","key":"10.1016\/j.mayocp.2016.12.025_bib24","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S0165-5728(03)00255-8","article-title":"Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study","volume":"142","author":"Confalonieri","year":"2003","journal-title":"J\u00a0Neuroimmunol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib25","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ejpn.2007.02.018","article-title":"Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I","volume":"11","author":"Darin","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib26","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/BOR.0000000000000335","article-title":"Spectrum of immune-mediated necrotizing myopathies and their treatments","volume":"28","author":"Pinal-Fernandez","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"7","key":"10.1016\/j.mayocp.2016.12.025_bib27","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.025_bib28","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.mayocp.2016.12.025_bib29","doi-asserted-by":"publisher","first-page":"e0141616","DOI":"10.1371\/journal.pone.0141616","article-title":"Clinical characteristics of anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibodies in Chinese patients with idiopathic inflammatory myopathies","volume":"10","author":"Ge","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jacc.2016.04.037","article-title":"Statin-induced anti-HMGCR-associated myopathy","volume":"68","author":"Basharat","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.mayocp.2016.12.025_bib31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: a history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.025_bib32","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/mus.25127","article-title":"Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy","volume":"54","author":"Floyd","year":"2016","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/CVM-2-5-205","article-title":"Withdrawal of cerivastatin from the world market","volume":"2","author":"Furberg","year":"2001","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.mayocp.2016.12.025_bib34","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1136\/ard.60.2.116","article-title":"Autoantibody profiles in the sera of European patients with myositis","volume":"60","author":"Brouwer","year":"2001","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.025_bib36","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/art.11484","article-title":"Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy","volume":"50","author":"Kao","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib37","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.mayocp.2016.12.025_bib38","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","volume":"87","author":"Watanabe","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"pt 8","key":"10.1016\/j.mayocp.2016.12.025_bib39","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1093\/brain\/aww054","article-title":"High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody","volume":"139","author":"Allenbach","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.025_bib40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gene.2016.04.029","article-title":"HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells","volume":"587","author":"Chushi","year":"2016","journal-title":"Gene"},{"issue":"1-2","key":"10.1016\/j.mayocp.2016.12.025_bib41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jneuroim.2013.08.008","article-title":"Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM)","volume":"264","author":"Rojana-udomsart","year":"2013","journal-title":"J\u00a0Neuroimmunol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/archneurol.2011.1728","article-title":"Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome","volume":"69","author":"Suzuki","year":"2012","journal-title":"Arch Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.025_bib43","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/RHU.0b013e31828e6442","article-title":"Signal recognition antibody-positive myopathy and response to intravenous immunoglobulin G (IVIG)","volume":"19","author":"Garcia-Rosell","year":"2013","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib44","doi-asserted-by":"publisher","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.mayocp.2016.12.025_bib45","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.nmd.2016.08.013","article-title":"Treatment and outcomes in necrotising autoimmune myopathy: an Australian perspective","volume":"26","author":"Ashton","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.025_bib46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/joim.12480","article-title":"Diagnostic criteria for inclusion body myositis","volume":"280","author":"Hilton-Jones","year":"2016","journal-title":"J\u00a0Intern Med"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib47","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ncl.2014.04.001","article-title":"Inclusion body myositis","volume":"32","author":"Dimachkie","year":"2014","journal-title":"Neurol Clin"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib48","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.clinph.2015.12.011","article-title":"Sporadic inclusion body myositis: a review of recent clinical advances and current approaches to diagnosis and treatment","volume":"127","author":"Needham","year":"2016","journal-title":"Clin Neurophysiol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib49","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/mus.24060","article-title":"Inclusion-body myositis presenting with facial diplegia","volume":"49","author":"Ghosh","year":"2014","journal-title":"Muscle Nerve"},{"issue":"11","key":"10.1016\/j.mayocp.2016.12.025_bib50","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.jocn.2013.06.004","article-title":"Sporadic inclusion body myositis presenting with severe camptocormia","volume":"20","author":"Ma","year":"2013","journal-title":"J\u00a0Clin Neurosci"},{"issue":"8","key":"10.1016\/j.mayocp.2016.12.025_bib51","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.clinph.2013.03.002","article-title":"Sleep disordered breathing in a cohort of patients with sporadic inclusion body myositis","volume":"124","author":"Della Marca","year":"2013","journal-title":"Clin Neurophysiol"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.025_bib52","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.nmd.2014.08.003","article-title":"Sleep disordered breathing and subclinical impairment of respiratory function are common in sporadic inclusion body myositis","volume":"24","author":"Rodr\u00edguez Cruz","year":"2014","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.025_bib53","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4103\/0028-3886.128313","article-title":"Inclusion body myositis involving the diaphragm: report of a pathologically confirmed case","volume":"62","author":"Martin","year":"2014","journal-title":"Neurol India"},{"issue":"pt 11","key":"10.1016\/j.mayocp.2016.12.025_bib54","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib55","first-page":"447","article-title":"The heart in sporadic inclusion body myositis: a study in 51 patients","volume":"257","author":"Cox","year":"2010","journal-title":"J\u00a0Neurol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib56","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.025_bib57","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC International Workshop: inclusion body myositis, 2-4 December 2011, Naarden, The Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"pt 5","key":"10.1016\/j.mayocp.2016.12.025_bib58","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1093\/brain\/aww024","article-title":"Association of inclusion body myositis with T cell large granular lymphocytic leukaemia","volume":"139","author":"Greenberg","year":"2016","journal-title":"Brain"},{"issue":"pt 5","key":"10.1016\/j.mayocp.2016.12.025_bib59","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/brain\/aww053","article-title":"Cytotoxic T cells go awry in inclusion body myositis","volume":"139","author":"Hohlfeld","year":"2016","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib60","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5\u2032-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib61","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5\u2032-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.025_bib62","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/jnnp-2014-310008","article-title":"Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement","volume":"87","author":"Goyal","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.025_bib63","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1136\/annrheumdis-2014-206691","article-title":"Disease specificity of autoantibodies to cytosolic 5\u2032-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases","volume":"75","author":"Herbert","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.025_bib64","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2119\/molmed.2015.00168","article-title":"BACE-1, PS-1 and sAPP\u03b2 levels are increased in plasma from sporadic inclusion body myositis patients: surrogate biomarkers among inflammatory myopathies [published online ahead of print November 3, 2015]","volume":"21","author":"Catal\u00e1n-Garc\u00eda","year":"2015","journal-title":"Mol Med"},{"issue":"10","key":"10.1016\/j.mayocp.2016.12.025_bib65","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.neurol.2016.07.016","article-title":"Sporadic inclusion-body myositis: recent advances and the state of the art in 2016","volume":"172","author":"Gallay","year":"2016","journal-title":"Rev Neurol (Paris)"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.025_bib66","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2014.09.012","article-title":"Inclusion body myositis: a review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches","volume":"22","author":"Mastaglia","year":"2015","journal-title":"J\u00a0Clin Neurosci"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib67","doi-asserted-by":"publisher","first-page":"e88788","DOI":"10.1371\/journal.pone.0088788","article-title":"Th1 response and systemic treg deficiency in inclusion body myositis","volume":"9","author":"Allenbach","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.mayocp.2016.12.025_bib68","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.clineuro.2011.03.016","article-title":"The association of sporadic inclusion body myositis and Sj\u00f6gren's syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype","volume":"113","author":"Rojana-udomsart","year":"2011","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib69","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/BOR.0000000000000213","article-title":"Genetic advances in sporadic inclusion body myositis","volume":"27","author":"Gang","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.025_bib70","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.nmd.2014.12.009","article-title":"Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis","volume":"25","author":"Weihl","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"24","key":"10.1016\/j.mayocp.2016.12.025_bib71","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib72","doi-asserted-by":"publisher","first-page":"e0154746","DOI":"10.1371\/journal.pone.0154746","article-title":"Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies","volume":"11","author":"Mugii","year":"2016","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.mayocp.2016.12.025_bib73","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1001\/jamadermatol.2016.1429","article-title":"Ovoid palatal patch in dermatomyositis: a novel finding associated with anti-TIF1\u03b3 (p155) antibodies","volume":"152","author":"Bernet","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib74","doi-asserted-by":"publisher","first-page":"e0155381","DOI":"10.1371\/journal.pone.0155381","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib75","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00408-016-9896-x","article-title":"Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease","volume":"194","author":"Johnson","year":"2016","journal-title":"Lung"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib76","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1055\/s-0032-1329201","article-title":"Idiopathic inflammatory myopathies","volume":"32","author":"Dimachkie","year":"2012","journal-title":"Semin Neurol"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib77","first-page":"470","article-title":"Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis","volume":"55","author":"Gitiaux","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.025_bib78","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.3899\/jrheum.090549","article-title":"Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA","volume":"36","author":"Antiochos","year":"2009","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.mayocp.2016.12.025_bib79","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40257-016-0199-z","article-title":"Amyopathic dermatomyositis: a concise review of clinical manifestations and associated malignancies","volume":"17","author":"Udkoff","year":"2016","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"10.1016\/j.mayocp.2016.12.025_bib80","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11926-014-0465-0","article-title":"Amyopathic dermatomyositis: definitions, diagnosis, and management","volume":"16","author":"Bailey","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"pt 7","key":"10.1016\/j.mayocp.2016.12.025_bib81","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1093\/brain\/aww122","article-title":"Microvascular alterations and the role of complement in dermatomyositis","volume":"139","author":"Lahoria","year":"2016","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.mayocp.2016.12.025_bib82","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1002\/art.22164","article-title":"A\u00a0novel autoantibody to a 155-kd protein is associated with dermatomyositis","volume":"54","author":"Targoff","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.mayocp.2016.12.025_bib83","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib84","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/WNL.0000000000002863","article-title":"Anti-TIF1-\u03b3 antibody and cancer-associated myositis: a clinicohistopathologic study","volume":"87","author":"Hida","year":"2016","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib85","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1002\/art.24547","article-title":"Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib86","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3109\/s10165-012-0663-4","article-title":"Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease","volume":"23","author":"Sato","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib87","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto","year":"2016","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.025_bib88","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/ana.410270402","article-title":"Microvascular changes in early and advanced dermatomyositis: a quantitative study","volume":"27","author":"Emslie-Smith","year":"1990","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.mayocp.2016.12.025_bib89","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/BOR.0b013e3282efe261","article-title":"A\u00a0gene expression approach to study perturbed pathways in myositis","volume":"19","author":"Greenberg","year":"2007","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"10.1016\/j.mayocp.2016.12.025_bib90","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.nmd.2015.04.013","article-title":"Disease course and therapeutic approach in dermatomyositis: a four-center retrospective study of 100 patients","volume":"25","author":"Johnson","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.mayocp.2016.12.025_bib91","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.berh.2016.04.007","article-title":"Idiopathic inflammatory myositis","volume":"30","author":"Tieu","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.mayocp.2016.12.025_bib92","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","article-title":"Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy","volume":"94","author":"Joffe","year":"1993","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib93","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mayocp.2016.12.025_bib94","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","article-title":"A\u00a0randomized, pilot trial of etanercept in dermatomyositis","volume":"70","year":"2011","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.mayocp.2016.12.025_bib95","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","article-title":"Consensus-based recommendations for the management of juvenile dermatomyositis","volume":"76","author":"Enders","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617300769?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619617300769?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T02:23:55Z","timestamp":1535855035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619617300769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0025619617300769"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.12.025","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Immune-Mediated Myopathies","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2016.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}